Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2810 - Prediction of total clearance by UGT1A and ABC genes polymorphisms can predict tumor response and proteinuria in axitinib treatment for advanced renal cell carcinoma


09 Oct 2016


Poster display


Hideyasu Matsuyama


Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373


H. Matsuyama1, Y. Yamamoto2, Y. Kawai2, Y. Fujita3, Y. Hamamoto3, K. Matsuyama4, T. Otori4, J. Haginaka5

Author affiliations

  • 1 Urology, Yamaguchi University Graduate School of Medicine, 755-8505 - Ube/JP
  • 2 Urology, Yamaguchi University Graduate School of Medicine, Ube/JP
  • 3 Computer Science And Systems Engineering, Yamaguchi University Graduate School of Medicine, Ube/JP
  • 4 Pharmacy, Kinki University, Higashiosaka/JP
  • 5 Pharmacy And Pharmaceutical Sciences, Mukogawa Women's University, Mukogawa/JP


Abstract 2810


Although axitinib is effective VEGF Tyrosine kinase inhibitor (TKI) for metastatic renal cell carcinoma (RCC), optimal initial dose remains unclear because dosing regimen relies to hypertension. We aimed to study if pharmaco-kinetic (PK) data has any relation to clinical efficacy/adverse event, and to establish the formulation of model that predict clinical efficacy and adverse events.


We prospectively evaluated the percent tumor reduction and adverse events in 40 patients (mean age: 66) treated with axitinib (median: 10mg/day) for advanced RCC (clear cell: 34, non-clear cell: 6). Gene polymorphisms of metabolic enzymes of axitinib (CYP3A4, UGT1A, ABCG2), and ABC transporter (BCRP, MDR-1) were analyzed using DNA chip, and PK data (AUC, total clearance, Cmax) were calculated from serum axitinib concentration measured by LC MS/MS. To construct the prediction model for PK data, exponential regression model was applied using 6 SNP data, with or without prior systemic therapies, and initial dose of axitinib as covariates.


Eleven of 34 evaluable patients (32%) had % tumor reduction >30% with a median of 13.5%. Major adverse events (Grade 3) were hypertension in 17 (43%), proteinuria in 7 (18%), respectively. Among several PK parameters, total clearance (CL-tot; dosage/AUC) was the most significantly associated with patient outcomes, i.e., reverse correlation with % reduction (R2 = 0.2542, p = 0.0017), and with proteinuria (p = 0.0058). There was a significant correlation between estimated CL-tot by prediction model and actual CL-tot (r2 = 0.6356, p 


Estimated CL-tot may be more beneficial than hypertension to determine the optimal initial dose of axitinib in individual RCC patient.

Clinical trial identification

UMIN000011147 (2013/07/10)

Legal entity responsible for the study

Institutional Review Board Yamaguchi University Hospital


Yamaguchi University Hospital Yamaguchi Prefecture


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings